Tanezumab reduces osteoarthritis knee pain, phase II study finds

Just months after a pharmaceutical company halted studies of tanezumab, a drug used in reducing pain and improving function in people with moderate-to-severe osteoarthritis of the knee, the results of a small, phase II clinical trial found only a few minor side effects and substantial improvement in patient conditions.

Read the whole article on Science Daily

More from Science Daily